| What would the Expert do? |
| 07.15-08.15 |
King’s Suite, HIC |
Chair: Jones H (Barnsley) |
|
|
When to replace testosterone |
|
|
|
Wu FCW (Manchester) |
|
| |
|
|
|
| British Thyroid Association
Pitt-Rivers Lecture |
| GENEROUSLY SUPPORTED BY THE BRITISH
THYROID ASSOCIATION |
| 08.30-09.30 |
Main Auditorium, HIC |
Chair: Kendall-Taylor P (Newcastle upon
Tyne) |
| S4 |
08.30 |
Molecular genetics of congenital
hypothyroidism |
|
|
Di Lauro R (Naples) |
|
| |
|
|
|
| TEA/COFFEE |
| 09.30-10.00 |
Hall D, HIC |
|
| |
|
|
|
| Symposium 4: Differentiated
thyroid cancer |
| GENEROUSLY SUPPORTED BY GENZYME
THERAPEUTICS |
| 10.00-12.00 |
Main Auditorium, HIC |
Chair: Kendall-Taylor P (Newcastle upon
Tyne) |
| S18 |
10.00 |
Initiating oncogenic events in thyroid
follicular cells: impact on chromosomal instability and disease progression |
| |
|
Fagin JA (Cincinnati) |
|
| S19 |
10.30 |
Improving the utility of fine needle
aspiration biopsy of thyroid tumours |
|
|
Haugen BR (Colorado) |
|
| S20 |
11.00 |
Differentiated thyroid cancer (DTC):
treatment outcomes |
|
|
Mazzaferri EL (Gainesville) |
|
| S21 |
11.30 |
UK thyroid cancer guidelines |
|
|
|
Franklyn JA (Birmingham) |
|
| |
|
|
|
| Symposium 5: Metalloproteinases
and their inhibitors: regulators of endocrine activity |
| 10.00-12.00 |
Royal Hall, HIC |
Chair: Holly JMP (Bristol) & Logan A
(Birmingham) |
| S22 |
10.00 |
The biology of matrix metalloproteinases
and their inhibitors |
|
|
Nagase H (London) |
|
| S23 |
10.30 |
Matrix metalloproteinases, cytokines
and bone/cartilage remodelling |
|
|
Maciewicz RA (Macclesfield),
Bowyer J, Brownrigg N, Goodwin L, Pickford R, Tessier J, Waterton J & Westwood
R |
| S24 |
11.00 |
Metalloproteinases and the modulation
of growth hormone signalling |
|
|
Baumann G (Chicago) & Frank
S |
| S25 |
11.30 |
The functional role of matrix-degrading
proteinases and their inhibitors in the female reproduction system |
|
|
Ny T (Umeå), Wahlberg P & Brandstrom
IJM |
| |
|
|
| Young Endocrinologists Session:
Good paper writing skills |
| 10.00-12.00 |
King’s Suite, HIC |
Chair: Fowkes R (London) & Renshaw D
(London) |
|
10.00 |
Basic flaws in data analysis |
|
|
Butler T (Newcastle) |
|
10.20 |
Data presentation skills |
|
|
McNeilly A (Edinburgh) |
|
10.40 |
How to write a good discussion |
|
|
Leng G (Edinburgh) |
|
11.00 |
Ethical considerations when paper
writing |
|
|
Chew S (London) |
|
11.20 |
How to deal with a rejection |
|
|
Clark A (London) |
|
11.40 |
Quality or quantity? |
|
|
Hillier S (Edinburgh) |
| |
|
|
| Oral Communications 4: Metabolism |
| 10.00-12.00 |
Spa Suite, Majestic Hotel |
Chair: Kumar S (Birmingham) & Connell
JMC (Glasgow) |
| OC25 |
10.00 |
Programming of adult adipose tissue
metabolism by prenatal glucocorticoids in the rat |
|
|
Cleasby ME, Walker BR & Seckl
JR |
| OC26 |
10.15 |
Impact of thiazolidinediones on
cardiovascular disease risk factors |
|
|
Marchetti A, Boyle PJ, King AB,
Olansky L, Lau H, Magar R & Martin J
A section of this research has been previously published in Clinical
Therapeutics Vol. 24, No. 3, March 2002.
Title: Effects of pioglitazone and rosiglitazone on blood lipids levels
and glycemic control in patients with type 2 diabetes mellitus: a retrospective
review of randomly selected medical records.
Authors: PJ Boyle, AB King, L Olanksy, A Marchetti, H Lau, R Magar & J
Martin |
| |
|
|
| OC27 |
10.30 |
A digenic basis for severe insulin
resistance in a large UK kindred - cosegregation of mutations in PPARg and
PPP1R3 |
|
|
Gurnell M, Savage DB, Agostini
M, Barroso I, Rajanayagam O, Soos M, Ross R, Schafer A, O’Rahilly
S & Chatterjee VKK |
| |
|
|
| OC28 |
10.45 |
Rosiglitazone inhibits insulin-mediated
rise in angiotensinogen expression and angiotensin II secretion in human
subcutaneous adipocytes |
|
|
Harte AL, McTernan PG, Smith
SA, Barnett AH & Kumar S |
| OC29 |
11.00 |
Deleterious effect of non-esterified
free fatty acids (NEFAs) on resistance artery endothelial function |
|
|
Sainsbury CAR, Hillier C, Sattar
N, Petrie JR & Connell JMC |
| OC30 |
11.15 |
Increased muscle oxidation of dietary
lipid contributes to oestrogen-induced improvements in postprandial lipid
metabolism |
|
|
Masding MG, Stears AJ, Gelauf
C, Burdge GC, Wootton SA & Sandeman DD |
| OC31 |
11.30 |
An interaction between ghrelin and
a species of high-density lipoprotein |
|
|
Beaumont NJ, Tan TM-M, Skinner
VO, Ramesh BS, Byrne DJ, Mikhailidis DP, Bouloux PM, Srai SK & Vanderpump
MP |
| OC32 |
11.45 |
Regulation of leptin receptor cleavage |
|
|
Maamra M, Bidlingmaier M, Postel-Vinay
MC, Wu Z, Strasburger CJ & Ross RJM |
| |
|
|
| British Thyroid Association
Annual General Meeting |
| 12.00-13.00 |
King’s Suite, HIC |
| |
|
|
| LUNCH |
| 12.00-13.30 |
Hall D, HIC |
| |
|
|
| Novartis Pharmaceuticals
UK Satellite Symposium: Delivering high quality acromegaly care |
| 12.30-13.30 |
Main Auditorium, HIC |
| |
|
|
| What would the Expert do? |
| 12.30-13.30 |
Royal Hall, HIC |
Chair: Brass A (Manchester) |
|
|
DNA analysis |
|
|
Sgouros J (London) |
| |
|
|
| What would the Expert do? |
| 12.30-13.30 |
Spa Suite, Majestic Hotel |
Chair: Davis J (Manchester) |
|
|
Vectors for gene transfer in endocrinology:
from in vitro to in vivo applications |
|
|
Uney J (Bristol) |
| Novartis Awards Poster Session |
| 13.30-14.00 |
Hall D, HIC |
|
| |
|
|
| Attended Posters (odd numbers) |
| 13.30-15.00 |
Hall D, HIC |
| |
|
|
| Endocrine Nurses Interactive
Workshops |
| 13.45-14.45 |
Conference Suite, HIC |
|
|
How to set up and manage nurse-led
clinics |
|
|
Holmes C (Cambridge) & MacFarlane
K (Edinburgh) |
|
|
The individual’s approach to
accessing accreditation of work-based learning |
|
|
Harris MM (Newcastle upon Tyne) |
| |
|
|
| Symposium 6: Cell-based
therapies for treating neuroendocrine disease |
| 15.00-17.00 |
Royal Hall, HIC |
Chair: Charlton H (Oxford) |
| S26 |
15.00 |
Embryonic stem cells: their potential
for therapeutics |
|
|
Li M (Edinburgh) |
| S27 |
15.30 |
Human neural stem cells: a therapeutic
modality for neurodegenerative disease |
|
|
Caldwell M (Cambridge) & Burnstein
R |
| S28 |
16.00 |
Engineering cells to treat diabetes |
|
|
Docherty K (Aberdeen) |
| S29 |
16.30 |
Repairing and protecting neurones,
a dual goal for cell based therapy to the brain |
|
|
Peschanski M (Creteil) |
| |
|
|
| Clinical Management Workshop 3: Unconventional
uses of thyroid hormones |
| 15.00-17.00 |
Main Auditorium, HIC |
Chair: Weetman AP (Sheffield) |
| S40 |
|
T3/T4 combination therapy |
|
|
|
Toft AD (Edinburgh) |
| S41 |
|
Unconventional uses of thyroid hormones: psychiatric
indications in mood disorder |
|
|
Whybrow P (Los Angeles), Bauer M & Altshuler
L |
| S42 |
|
Cardiac indications |
|
|
|
Bonser RS (Birmingham) |
| |
|
|
|
| Nurses Session: Advances
in diagnostic imaging |
| 15.00-17.00 |
King’s Suite, HIC |
Chair: Musson P (Southampton) & Miller
M (Newcastle upon Tyne) |
| |
|
|
|
|
15.00 |
Advanced radiological techniques
employed in endocrine tumour localisation |
|
|
Richardson B (Newcastle upon
Tyne) |
|
15.30 |
The management of selective intra-arterial
venous sampling with calcium stimulation in insulinoma localisation |
|
|
Yeoh P (London) |
|
15.45 |
Positron emission tomography (PET),
targeted radionuclide imaging and therapy in nuclear endocrinology |
|
|
Buxton Thomas M (London) |
|
16.15 |
Patient preparation, information
provision, and safety precautions in the presence of radioactive isotopes |
|
|
Roberts M (Manchester)
|
|
|
CASE PRESENTATIONS |
|
|
16.30 |
Persistent hyper-insulinaemic hypoglycaemia
in infancy |
|
|
Gilbert C (London) |
|
16.37 |
Confirming the diagnosis in infant
hypothyroidism |
|
|
Ward S (London) |
|
16.44 |
Finding the phaeochromocytoma |
|
|
Frewin S (Newcastle upon Tyne) |
|
16.51 |
Management of insulin |
|
|
Rodgers B (Dublin) |
| |
|
|
|
| Oral Communications 5: Hormone
action |
| 15.00-17.00 |
Spa Suite, Majestic Hotel |
Chair: Ray DW (Manchester) & Williams
GR (London) |
| OC33 |
15.00 |
The role of the PPARg in
thyroid eye disease: possible contra-indication for thiazolidenedione therapy |
|
|
Starkey KJ, Heufelder AE, Evans
LM, Davies JS, Baker G & Ludgate M |
| OC34 |
15.15 |
Iodothyronine deiodinase expression
in thyroid responsive fetal tissues |
|
|
Chan S, Kachilele S, McCabe CJ,
Tannahill L, Boelaert K, Gittoes N, Franklyn JA & Kilby MD |
| OC35 |
15.30 |
Modification of calcium sensing receptor expression
modulates 25-hydroxyvitamin D3-1a-hydroxylase
activity in a human proximal tubule cell line |
|
|
Bland R, Zehnder D, Hughes SV, Rao AR, Stewart
PM & Hewison M |
| OC36 |
15.45 |
Increasing fracture risk with age: possible role
of local corticosteroid generation |
|
|
Cooper MS, Rabbitt EH, Hewison M & Stewart
PM |
| OC37 |
16.00 |
Demonstration of progesterone receptor mediated
gonadotrophin suppression in men |
|
|
Brady BM, Anderson RA, Kinniburgh D & Baird
DT |
| OC38 |
16.15 |
Autocrine generation of androgens within adipose
tissue: implications for polycystic ovarian syndrome (PCOS) |
|
|
Sinha B, Tomlinson JW, Bujalska IJ, Hewison
M & Stewart PM |
| OC39 |
16.30 |
DHEA, a selective glucocorticoid receptor antagonist,
studies in human lymphoblasts and hepatocytes |
|
|
Sacco MS, Valenti GV, Corvi Mora PCM, Wu FCW & Ray
DW |
| OC40 |
16.45 |
RU486, the glucocorticoid receptor (GR) antagonist,
recruits NCoR, but not SRC-1: explaining type II antagonism |
|
|
Stevens A, Garside HJ & Ray DW |
| |
|
|
| TEA/COFFEE |
| 17.00-17.30 |
Hall D, HIC |
|
|
|
| NURSES TEA |
| GENEROUSLY SUPPORTED BY SERONO PHARMACEUTICALS |
| 17.00-17.30 |
Conference Suite, HIC |
| |
|
|
| Society for Endocrinology Dale Medal
Lecture |
| 17.30-18.30 |
Main Auditorium, HIC |
Chair: Franks S (London) |
| S5 |
17.30 |
Darwin, De Graaf and selection of the ovulatory
follicle(s) |
|
|
Baird DT (Edinburgh) |
| |
|
|
| BES Banquet (ticket only) |
| 19.30 |
Old Swan Hotel |